Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 346 clinical trials
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

In patients with locally advanced oral squamous cell carcinoma (OSCC), due to the large tumor burden and neck lymph node metastasis, comprehensive treatment is recommended, including surgery, radiotherapy, chemotherapy and others. Pre-operative inductive therapy can reduce tumor volume, increase organ retention rate, and reduce distant metastasis rate.

tumor burden
hypoxia
carcinoma
squamous cell carcinoma of the head and neck
cancer
  • 0 views
  • 19 Feb, 2024
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

EGFR
proto-oncogene tyrosine-protein kinase ros
carboplatin
pemetrexed
adjuvant therapy
  • 0 views
  • 19 Feb, 2024
The Application of Real-Time Near-infrared Imaging in Gynecological Surgery

Removing in situ and metastasis lesions completely during gynecological surgery is central to reduce the recurrence and death, and the identification of lesions in traditional gynecological surgery often depends on the experience of surgeons.

cyst
uterine myomatosis
indocyanine green
endometriosis
cancer
  • 0 views
  • 19 Feb, 2024
Irreversible Electroporation of Unresectable Liver Tumors

The aim of this study is to evaluate the safety and feasibility of curative intended irreversible electroporation (IRE) in the treatment of liver tumors neighboring major vessels or bile ducts.

metastasis
hepatoma
biliary tract cancer
liver tumor
cancer
  • 0 views
  • 19 Feb, 2024
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Background Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis.

pancreatic cancer
inherited long qt syndrome
pediatric
blood tests
cancer
  • 0 views
  • 19 Feb, 2024
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors

Hepatic metastases are common in solid cancers (up to 30% of patients with colorectal cancer and up to 50% of patients during their follow-up). The incidence of primary liver cancer increases due to the increase in chronic liver diseases induced by excessive alcohol consumption, hepatitis B and C viruses, and …

skin cancer
liver diseases
cancer
colorectal cancer
chelates
  • 0 views
  • 19 Feb, 2024
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and …

aptt
solid tumour
gastrointestinal cancer
g-csf
international normalized ratio
  • 0 views
  • 19 Feb, 2024
Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

Eligible patients have prostate cancer that was treated with surgery or radiation therapy for localized disease and there is evidence of biochemical recurrence and/or metastases on conventional imaging.The objective of this study is to assess the performance in detection of prostate cancer of a new positron emission tomography (PET) radiotracer …

pet/mri
fluciclovine (18f)
conventional imaging
positron emission tomography
metastasis
  • 0 views
  • 19 Feb, 2024
LYT-100 in Healthy Volunteers and BCRL

Part 3 is a trial of up to 6-months duration for safety, tolerability, PK, biomarkers and exploratory clinical assessments in breast carcinoma patients with secondary lymphoedema

cancer surgery
reconstructive surgery
lymphedema
nipple reconstruction
carcinoma
  • 0 views
  • 19 Feb, 2024
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

cutaneous t-cell lymphoma
chronic lymphocytic leukemia
cancer therapy
cancer
dexamethasone
  • 0 views
  • 19 Feb, 2024
  • 5 locations